We also observed that CMML-AML patients showed a high frequency of RUNX1 mutations (6/12; 50%) compared to CMML (11/97; 11.3%) patients, indicating that the RUNX1 mutation may have been acquired later during AML transformation (Figure 4B). This evidence concerns the gene RUNX1 and chronic myelomonocytic leukemia.